网站主页 >> CAS数据库列表 >> 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
|
|
|
- CAS号:
- 193746-75-7
- 英文名:
- SB242235
- 英文别名:
- CS-668;SB242235;SB242235 ≥95%;SB-242235; SB242235;inhibit,SB 242235,Autophagy,Inhibitor,p38 MAPK;4-[4-(4-Fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxypyrimidine;4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-iMidazol-5-yl)-2-MethoxypyriMidine;Pyrimidine, 4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxy-
- 中文名:
- 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
- 中文别名:
- 化合物SB242235;P38MAP激酶抑制剂(SB 242235);4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶;4-(4-(4-氟苯基)-1-(哌啶-4-基)-1H-咪唑-5-基)-2-甲氧基嘧啶
- CBNumber:
- CB12621150
- 分子式:
- C19H20FN5O
- 分子量:
- 353.39
- MOL File:
- 193746-75-7.mol
|
|
|
4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶化学性质
-
沸点:
-
568.4±60.0 °C(Predicted)
-
|
-
密度:
-
1.34
-
|
-
储存条件:
-
2-8°C(protect from light)
-
|
-
溶解度:
-
DMF: 25 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml
-
|
-
形态:
-
Powder
-
|
-
酸度系数(pKa):
-
9.91±0.10(Predicted)
-
|
4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶性质、用途与生产工艺
SB-242235 是一种有效、选择性的 p38 MAP 激酶抑制剂，在人的软骨细胞中 IC50 值为 1.0 μM。
IC50: 1.0 μM (p38 MAPK, primary human chondrocytes)
SB 242235 (0-10 μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC
50
of 1.0 μM in human chondrocytes stimulated with IL-1β.
SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate.
Western Blot Analysis
|
Cell Line:
|
Human chondrocytes
|
|
Concentration:
|
0 μM,0.01 μM,0.1 μM,1 μM,10 μM
|
|
Incubation Time:
|
15 minutes
|
|
Result:
|
Dose-dependently inhibited the activation of MAPKAP K2 with an
IC
50
of 1.0 μM.
|
SB242235 (100 mg/kg; p.o.) abolishes MAP-KAPK-2 activity and HSP27 phosphorylation.
SB242235 inhibits expression of the pro-inflammatory cytokines interleukin (IL)-6 and KC (murine IL-8) and COX-2.
SB-242235 is demonstrated non-linear elimination kinetics that manifested as a decrease in clearance with increasing dose and apparent oral bioavailability > 100% at high oral doses in rat and monkey.
|
Animal Model:
|
Female SKH-1 hairless mice (4–6 weeks)
|
|
Dosage:
|
100 mg/kg
|
|
Administration:
|
Oral administered, 30 minutes prior to ultraviolet B (UVB) irradiation
|
|
Result:
|
Abolished MAP-KAPK-2 activity and heat shock protein 27 (HSP27) phosphorylation.
|
4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-18306 | 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
SB 242235 | 193746-75-7 | 5mg | 850元 |
| 2024/01/25 | HY-18306 | 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
SB 242235 | 193746-75-7 | 10mM * 1mLin DMSO | 935元 |
4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
生产厂家
193746-75-7, 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶 相关搜索:
SB743921;(R)-N-(3-AMINOPROPYL)-N-(1-(3-BENZYL-7-CHLORO-4-OXO-4H-CHROMEN-2-YL)-2-METHYLPROPYL)-4-METHYLBENZAMIDEHYDROCHLORIDE (2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺 SB225002 SB216763 3-苯基磺酰基-8-(哌嗪-1-基)喹啉 SB-3CT 6-氯-2,3-二氢-5-甲基-N-[6-[(2-甲基-3-吡啶基)氧]-3-吡啶基]-1H-吲哚-1-酰胺盐酸盐 3-[(3-氯-4-羟苯基)氨基]-4-(2-硝苯基)-1H-吡咯-2,5-二酮 4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑 SB-431542 5-[2-[4-[2-(二甲基氨基)乙氧基]苯基]-5-(4-吡啶基)-1H-咪唑-4-基]-2,3-二氢-1-茚酮肟 SB269970盐酸盐 14-甲基-20-氧杂-5,7,14,27-四氮杂四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2,4,6(27),8,10,12(26),16,21,23-十烯 6-[2-(1,1-二甲基乙基)-5-(6-甲基-2-吡啶基)-1H-咪唑-4-基]喹喔啉 3-(4-氯苯基)-N-(3-甲氧基苯基)-2-丙烯酰胺 SB-705498 4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑 SB-505124
- 细胞生物学试剂
- 4-(4-(4-氟苯基)-1-(哌啶-4-基)-1H-咪唑-5-基)-2-甲氧基嘧啶
- 化合物SB242235
- P38MAP激酶抑制剂(SB 242235)
- 4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶
- 193746-75-7
- inhibit,SB 242235,Autophagy,Inhibitor,p38 MAPK
- Pyrimidine, 4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxy-
- SB242235 ≥95%
- CS-668
- SB-242235; SB242235
- 4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-iMidazol-5-yl)-2-MethoxypyriMidine
- 4-[4-(4-Fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxypyrimidine
- SB242235